The boards of Pfizer and Ireland's Allergan on Sunday approved a merger deal worth $160 billion. The deal would create the largest drugmaker by sales.
Pharmaceutical giants Pfizer and Allergan are reportedly nearing a blockbuster deal that could be announced as soon as this week.
An expected deal between pharmaceutical giants Pfizer and Allergan that's expected to be worth up to $380 a share could become less lucrative under new U.S. Treasury rules designed to diminish the benefits of cross-border transactions.
The healthcare industry added 44,900 jobs in October. This year, the industry has created almost 407,000 jobs, which almost equals the 410,000 jobs the industry added in 2013 and 2014 combined.
Pharmaceutical giant Pfizer said Thursday that it would double the income threshold for patients to be eligible for financial assistance in response to an increasing number of consumers finding it difficult to afford their prescription medicines.
A host of U.S. healthcare companies will be affected by a decision by Europe's highest court earlier this week to toss out a 15-year data-sharing compact between the U.S. and members of the European Union.
Diabetic patients are a popular target population for health systems that hope to improve patients' health with better care coordination and closer management. But new data from the research collaborative OptumLabs suggest diabetes management can be too aggressive.
Drugmaker Pfizer says it has completed its roughly $15 billion purchase of the injectable-drug maker and infusion-device manufacturer Hospira, expanding its product offerings in a growing medical market.
Drugmaker Pfizer says it's received the final regulatory approvals for its $15.23 billion purchase of the injectable drug and infusion devicemaker Hospira, and says the deal will close in early September. The FTC has ordered Pfizer to sell four drugs in order to preserve competition.
Pharmaceutical giant Pfizer on Tuesday reported continuing declines in sales and earnings as it girds for the loss of patent protection in Europe and Japan of Enbrel, its rheumatoid arthritis drug.
Florida Hospital DeLand is one of three hospitals in the state testing an experimental anti-venom for coral snake bites. The brightly colored snake rarely bites, but just a drop of its venom is a lethal dose.
The federal government is launching a very different kind of cancer study that will assign patients drugs based on what genes drive their tumors rather than the type.